Antiplatelet Therapy and Cardiovascular Diseases
Antiplatelet Therapy and Cardiovascular Diseases is a research topic within Cardiology and Cardiovascular Medicine. Science Explorer counts 32k research works in it since 1950. 17.1% of them reached the world's top 10% most cited for their field and year.
This cluster of papers focuses on the use of antiplatelet therapy, including aspirin, clopidogrel, and ticagrelor, in the prevention of cardiovascular events, especially in the context of percutaneous coronary intervention. It also explores the impact of genetic polymorphisms, platelet reactivity, and bleeding risk on the efficacy and safety of antiplatelet drugs.
- Aspirin
- Clopidogrel
- Ticagrelor
- Platelet Reactivity
- Cardiovascular Events
- Percutaneous Coronary Intervention
- Genetic Polymorphisms
- Bleeding Risk
- Thrombotic Events
- CYP2C19 Genotype
- Research works
- 32k fractional, since 1950
- In the world top 10%
- 5.4k per year above
- Top-10% rate
- 17.1% share of its works in the world top 10%
- Growth, 2013–17 → 2018–22
- +3% the tick is no change
This ranks research output and citation impact. It says nothing about the quality of diagnosis, treatment or care.
Which countries lead Antiplatelet Therapy and Cardiovascular Diseases research?
By volume, the United States and China publish the most (1k and 606 works in 2022–2025).
By volume, 2022–2025
- 1 United States 1k works
- 2 China 606 works
- 3 Italy 244 works
- 4 Germany 199 works
- 5 Japan 195 works
- 6 United Kingdom 190 works
- 7 South Korea 189 works
- 8 India 169 works
- 9 France 117 works
- 10 Spain 112 works
How concentrated that is
The same countries as shares of everything the list above accounts for. A node where two countries do two thirds of the work and one spread evenly across twelve read alike as a ranking and not at all alike here.
Shares of the rows listed above, not of the whole node.
Which institutions lead Antiplatelet Therapy and Cardiovascular Diseases research?
By volume in 2022–2025, Chinese Academy of Medical Sciences & Peking Union Medical College publishes the most Antiplatelet Therapy and Cardiovascular Diseases research, followed by Capital Medical University and Icahn School of Medicine at Mount Sinai.
By volume, 2022–2025
- 1 Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina 28 works
- 2 Capital Medical UniversityChina 19 works
- 3 Icahn School of Medicine at Mount SinaiUnited States 18 works
- 4 University of North Carolina at Chapel HillUnited States 17 works
- 5 Harvard UniversityUnited States 16 works
- 6 Massachusetts General HospitalUnited States 16 works
- 7 Brigham and Women's HospitalUnited States 14 works
- 8 University of FloridaUnited States 14 works
- 9 Medical University of ViennaAustria 14 works
- 10 Seoul National University HospitalSouth Korea 12 works
Who are the leading researchers in Antiplatelet Therapy and Cardiovascular Diseases?
The most-cited researchers publishing on Antiplatelet Therapy and Cardiovascular Diseases include Graeme J. Hankey, Gordon Guyatt and Valentı́n Fuster.
- 1 Graeme J. Hankey Australia 7.2k citations
- 2 Gordon Guyatt Canada 6.8k citations
- 3 Valentı́n Fuster United States 5.4k citations
- 4 Maciej Banach Poland 5.2k citations
Ranked by citations received across their whole record, among researchers with at least three works on this topic.
Where is Antiplatelet Therapy and Cardiovascular Diseases research done?
The largest centres of Antiplatelet Therapy and Cardiovascular Diseases research in 2022–2025 are Beijing (China), Seoul (South Korea), New York (United States) and Moscow (Russia).
Largest cities, 2022–2025
Where is the best place to study Antiplatelet Therapy and Cardiovascular Diseases?
Among universities, judged by research, Icahn School of Medicine at Mount Sinai, Medical University of Vienna and Chinese Academy of Medical Sciences & Peking Union Medical College score highest, combining excellence, specialisation, size, growth and international reach. Research strength is one signal when choosing where to study; it does not measure teaching.
One dot per university in the table below. The upper left is the interesting corner: small places doing unusually strong work.
| # | University | Score | Top 10% | Specialisation | Works | Growth |
|---|---|---|---|---|---|---|
| 1 | Icahn School of Medicine at Mount SinaiUnited States | 66.4 | 15.8% | 8.6× | 18 | +92.3% |
| 2 | Medical University of ViennaAustria | 61.4 | 19.3% | 10.5× | 14 | -16.3% |
| 3 | Chinese Academy of Medical Sciences & Peking Union Medical CollegeChina | 58.7 | 13.9% | 6.7× | 28 | +47.5% |
| 4 | Florida CollegeUnited States | 57.7 | 30.4% | 17.8× | 10 | -31.6% |
| 5 | University of LiverpoolUnited Kingdom | 53.8 | 33.9% | 3.8× | 8 | +21.3% |
| 6 | Harvard UniversityUnited States | 52.0 | 26.3% | 2.9× | 16 | +12.6% |
| 7 | Capital Medical UniversityChina | 47.4 | 11.7% | 7.5× | 19 | +11.3% |
| 8 | University of FloridaUnited States | 45.8 | 28.6% | 3.1× | 14 | -0.4% |
| 9 | University of MichiganUnited States | 35.6 | 18.2% | 2.0× | 12 | +42.9% |
| 10 | McMaster UniversityCanada | 34.1 | 20.0% | 3.8× | 8 | -16.4% |
Universities only. Score blends excellence (30%), specialisation (25%), size (20%), growth (15%) and international reach (10%), 2015–2022; growth compares 2010–14 with 2015–19.
Is Antiplatelet Therapy and Cardiovascular Diseases research growing?
Output in 2018–2022 was 3% higher than in 2013–2017, peaking in 2025. The fastest-growing topics are Antiplatelet Therapy and Cardiovascular Diseases.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Which topics inside it are moving
Growth and decline on one axis around a shared zero. Two lists side by side hide the thing that matters: whether the growth dwarfs the decline, or the other way round.